Bhupendra Krishna, MD | |
330 Longwood Road, Kennett Square, PA 19348 | |
(610) 388-6862 | |
Not Available |
Full Name | Bhupendra Krishna |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Location | 330 Longwood Road, Kennett Square, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790980621 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | MD032454L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Bhupendra Krishna, MD 330 Longwood Road, Kennett Square, PA 19348 Ph: (610) 388-6862 | Bhupendra Krishna, MD 330 Longwood Road, Kennett Square, PA 19348 Ph: (610) 388-6862 |
News Archive
IQ Therapeutics B.V., Groningen, the Netherlands, announced this week that in collaboration with the University of Texas Medical Branch it has obtained outstanding results for the treatment of inhalation anthrax. In a rabbit model up to 100% survival could be achieved with extended time to treatment (48h post infection) with a combination of two specific monoclonal antibodies developed by IQ Therapeutics. This has significant potential for saving lives of infected people who have no immediate access to treatment.
People process information about financial loss through mechanisms in the brain similar to those used for processing physical pain, according to a new imaging study.
RadNet, Inc., a national leader in providing high-quality, fixed-site outpatient diagnostic imaging services through a network of 180 imaging centers, today announced the pricing of its offering of $200 million in aggregate principal amount of 10⅜% senior notes due 2018 at an issue price of 98.680%.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecules, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents - which target two of the most frequent KRAS mutations in cancer.
Hispanic women surveyed in the metro Detroit area were twice as likely as white women to be affected by vulvodynia, unexplained vulvar pain that can make sex, tampon use or even sitting excruciating. Meanwhile, the condition affected half as many black women, new University of Michigan research shows.
› Verified 4 days ago